Category: Dr. Edwards

ECTRIMS-ACTRIMS Congress meeting updates

Dr. Edwards is the author/co-author on a couple of posters at the 7th Joint ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) ACTRIMS meeting in Paris, October 25-28. Check out our  Scientific Meetings section to see the accepted posters.

From the Annual Meeting of the Consortium of MS Centers (CMSC), New Orleans

From Keith Edwards, MD   May 26, 2017 With the news of a MS patient in Germany who developed PML after 3 years of Tysabri and then one dose of ocrelizumab, the question of effectiveness and safety in ‘sequencing’ or switching from Tysabri (natalizumab) to another MS medication has become an even more important decision.  What… Read more »

Treatment goal in MS:  No evidence of disease activity (NEDA)

Current available management of MS can now limit, stop, or improve disability for the majority of patient with MS.  The management needs to be appropriate, safe, and effective to be of value.  No longer is it acceptable to continue a failed treatment. Management and treatment begin with good general health from diet and exercise to… Read more »

Treatment goal in MS: No evidence of disease activity (NEDA)

Current available management of MS can now limit, stop or improve disability for the majority of patient with MS.  The management needs to be appropriate, safe and effective to be of value.  No longer is it acceptable to continue a failed treatment. Management and treatment begin with good general health from diet and exercise to… Read more »

MS Treatment at the MS Center of NENY

ZINBRYTA (generic name, daclizumab) was FDA approved recently for relapsing forms of MS. The MS Center has been using this medication in clinical trials for 10 years. This medication was previously used for renal disease under the name of Zenapax since 1997. This medication modulates, or regulates, a specific immune process in the human body… Read more »

The Importance Of Vitamin D In MS

It has been known for over 50 years that there is less MS in populations that have more sunlight, with the exception of Northern Scandinavia where fish consumption is high. The common factor is Vitamin D. There is yet another research paper published this week in the Multiple Sclerosis Journal (issue April 1, 2016) showing… Read more »

MS does not have to be a disabling condition

Of course, when one is given the diagnosis of MS, the initial fear is “what will happen to me?” The goal of this MS Center is to prevent disability, whether this involves strength, balance, vision or cognition. Our understanding and treatment opinions with MS had finally gotten to where breast cancer was 20 years ago:… Read more »